Houston, TX – April 8th, 2026 – OmniScience announces expanded capabilities to integrate directly with Veeva TMF and Veeva CTMS, enabling sponsors to unify operational and clinical data into Vivo, the clinical trial Control Tower.
Clinical trials generate critical early signals across systems such as EDC, CTMS, TMF, labs, and external vendors. Historically, accessing and harmonizing this data has required layered approvals, commercial agreements, or restricted ecosystem participation. OmniScience removes these barriers, allowing sponsors to bring their data together on their terms and operationalize AI-driven oversight immediately.
Vivo continuously monitors unified trial data, detects meaningful change in real time, and interprets what’s driving those changes across sites, subjects, vendors, and endpoints. This enables teams to act earlier - before delays, risks, or cost impacts are locked in.
“Our view is simple: sponsors own their data, and they should be able to use it to improve trial outcomes without constraint,” said Angela Holmes, CEO of OmniScience. “We’ve built Vivo to integrate directly with the systems sponsors already rely on. This ensures teams can move faster while reducing costs to improve outcomes.”
By supporting direct integration with widely used clinical platforms, OmniScience enables:
For clinical operations and development leaders, this approach delivers immediate value without disruption, allowing organizations to layer advanced AI capabilities on top of existing infrastructure while maintaining full control of their data.
This reflects a broader shift in clinical development: from closed ecosystems and report-driven oversight toward open, interoperable, AI-driven execution models. As trials grow more complex, sponsors are increasingly prioritizing flexibility, transparency, and speed in how they operationalize data.
OmniScience is enabling that transition today.
